← All trials
NCT05242874
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2022
- Primary completion
- Jan 1, 2024
- Completion date
- Jun 1, 2024
- First posted
- Feb 16, 2022
- Last posted
- Apr 18, 2022
- Enrollment
- 403
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Henan Medical UniversityLead sponsor
- Henan Medical UniversityOverall official - principal investigator
- Henan Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.